The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company reported group revenue of US$230 million, up 11% quarter-over-quarter, and reaffirmed its FY 2026 revenue guidance.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Unaudited group revenue of US$230 million, up 11% from the previous quarter
- Precision Medicine revenue of US$186 million, a 16% quarter-over-quarter increase
- FY 2026 revenue guidance reaffirmed at US$950 million to US$970 million
- Successful early results from Phase 3 ProstACT® study of TLX591-Tx for prostate cancer
- Key regulatory submissions: Pixclara® NDA resubmitted to the US FDA and Pixlumi® MAA filed in Europe
What else do investors need to know?
Telix continues to advance its therapeutics pipeline, hitting milestones in global studies across prostate, brain, and kidney cancer. Notably, the company observed no new safety signals in the first part of the ProstACT study, supporting the safety profile of its lead prostate cancer candidate.
The company maintains strong momentum in its global expansion, now offering Illuccix in 21 countries, including 16 European nations. Its commercial presence is poised to support future product launches in both diagnostics and therapeutics.
Board renewal is underway, with David Gill set to join as Non-Executive Director in May and be appointed Chair in the future, bringing recognised governance and industry experience.
What did Telix Pharmaceuticals management say?
Managing Director and Group CEO Dr. Christian Behrenbruch said:
Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two-product PSMA imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.
What's next for Telix Pharmaceuticals?
Telix reaffirmed its FY 2026 revenue guidance, expecting further revenue growth driven by global uptake of its products and a full-year contribution from RLS Radiopharmacies. The company is targeting increased scale through new product launches and expanding its clinical program footprint across many markets.
R&D spend for the full year is forecast between US$200 million and US$240 million, subject to commercial progress. Telix is also moving forward with additional regulatory filings and study site activations in new countries, supporting a positive outlook for its pipeline.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 17% over the same period.
